US OptionsDetailed Quotes

ACRS240816P1000

Watchlist

0.05
0.000.00%

15min DelayClose Jul 26 15:58 ET

0.00High0.00Low

Aclaris Therapeutics Stock Discussion

Stock Region

Jul 19 12:55

Therapeutics Company Announces Royalty Sale For Up To $31.5 Million

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million.
On July 19, 2024, Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced the sale of a portion of its future royalty payments and certain milestones related to OLUMIANT® (baricitinib) to OMERS...

sriz

Jul 16 17:39

$Aclaris Therapeutics(ACRS.US)$ big news

Stock_Drift

Jul 16 16:57

Top Moo_vers are tagged. 🐮

$Shimmick(SHIM.US)$ $Aclaris Therapeutics(ACRS.US)$ $Aehr Test Systems(AEHR.US)$ $Hour Loop(HOUR.US)$ $China Green Agriculture(CGA.US)$

Wind_Storm

Jul 16 15:20

Let's Go!

$Aclaris Therapeutics(ACRS.US)$ Institutional Equity 77.7%

Wind_Storm

Jul 16 15:18

This should fly tomorrow

$Aclaris Therapeutics(ACRS.US)$
Aclaris Therapeutics Shares Are Trading Higher After the Company Announced the Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for up to $31.5 Million

Trytosaveabit

Jul 16 15:08

$Aclaris Therapeutics(ACRS.US)$ There is a gap that needs fillin to 4.59, Now fill it you hussie! hehehe

Trytosaveabit

Jul 16 15:04

Update

$Aclaris Therapeutics(ACRS.US)$ Reuters· 1 min ago1min
Aclaris Therapeutics Inc - Receives $26.5M Upfront Payment

Jaguar8

Jul 16 15:03

NEWS

$Aclaris Therapeutics(ACRS.US)$
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics (NASDAQ: ACRS) has announced the sale of a portion of its future royalty payments and certain milestones for OLUMIANT® (baricitinib) to OMERS Life Sciences for up to $31.5 million. The deal includes a $26.5 million upfront payment and up to $5.0 million in potential milestone payments based on OLUMIANT sales in 2024. Thi...

Trytosaveabit

Feb 27 06:21

Not bad!

$Aclaris Therapeutics(ACRS.US)$ Aclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55M

Moomoo AI

Jan 19 13:25

Aclaris Therapeutics' high P/S ratio, alongside declining revenue and the industry's predicted 49% annual growth, could be a significant risk for shareholders and potential investors.

There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 26% Price Jump

No comment yet